EP2496256A4 - Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité - Google Patents

Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Info

Publication number
EP2496256A4
EP2496256A4 EP10828938.0A EP10828938A EP2496256A4 EP 2496256 A4 EP2496256 A4 EP 2496256A4 EP 10828938 A EP10828938 A EP 10828938A EP 2496256 A4 EP2496256 A4 EP 2496256A4
Authority
EP
European Patent Office
Prior art keywords
poxvirus
immunoconjugates
subunit
peptides
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10828938.0A
Other languages
German (de)
English (en)
Other versions
EP2496256A2 (fr
Inventor
Alice P Taylor
Boby Makabi-Panzu
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Publication of EP2496256A2 publication Critical patent/EP2496256A2/fr
Publication of EP2496256A4 publication Critical patent/EP2496256A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP10828938.0A 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité Withdrawn EP2496256A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US25872909P 2009-11-06 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
PCT/US2010/054668 WO2011056721A2 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Publications (2)

Publication Number Publication Date
EP2496256A2 EP2496256A2 (fr) 2012-09-12
EP2496256A4 true EP2496256A4 (fr) 2013-07-17

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10828938.0A Withdrawn EP2496256A4 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Country Status (6)

Country Link
EP (1) EP2496256A4 (fr)
CN (1) CN102573902A (fr)
AU (1) AU2010315432A1 (fr)
CA (1) CA2776563A1 (fr)
IN (1) IN2012DN02692A (fr)
WO (1) WO2011056721A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014047124A1 (fr) * 2012-09-18 2014-03-27 University Of Washington Through Its Center For Commercialization Compositions et procédés d'administration d'antigènes à des cellules dendritiques plasmacytoïdes
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
EP3903818A1 (fr) 2015-11-19 2021-11-03 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
CN109187982B (zh) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 一种tlr类疫苗佐剂的筛选和鉴定方法
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
CA3117378A1 (fr) * 2018-10-22 2020-04-30 Icellkealex Therapeutics Llc Virus de la vaccine mutants et leur utilisation
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
AU2021265124A1 (en) * 2020-04-27 2022-11-03 Genovie Ab Methods to generate vaccine compositions that prime human leukocyte antigen class I restricted CD8 T-cell responses against viral non-virion-integral derived epitopes

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (fr) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Polypeptide de fusion au vih
WO1999036507A1 (fr) * 1998-01-15 1999-07-22 Genitrix, Llc Compositions de vaccin et procedes de modulation des reponses immunitaires
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (fr) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Complexe proteinique polyvalent
WO2006107786A2 (fr) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Structures ameliorees, attachees de façon stable, de compositions definies presentant diverses fonctions ou specificites de liaison
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (fr) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (fr) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Ensembles bio-actifs polyvalents a base d'immunoglobuline
WO2007134037A2 (fr) * 2006-05-15 2007-11-22 Immunomedics, Inc. Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
WO2009055653A1 (fr) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation par la technique d'accostage et verrouillage (dnl)
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
WO2009126558A1 (fr) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Procédé modulaire pour préparer des cytokines tétramères avec une pharmacocinétique améliorée par la technologie « dock-and-lock » (dnl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395422T1 (de) * 1995-06-07 2008-05-15 Sanofi Pasteur Ltd Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
JP4472351B2 (ja) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗ｃｄ７４抗体およびその使用方法
ES2829566T3 (es) * 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (fr) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Polypeptide de fusion au vih
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
WO1999036507A1 (fr) * 1998-01-15 1999-07-22 Genitrix, Llc Compositions de vaccin et procedes de modulation des reponses immunitaires
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (fr) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Complexe proteinique polyvalent
WO2006107786A2 (fr) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Structures ameliorees, attachees de façon stable, de compositions definies presentant diverses fonctions ou specificites de liaison
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (fr) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (fr) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Ensembles bio-actifs polyvalents a base d'immunoglobuline
WO2007134037A2 (fr) * 2006-05-15 2007-11-22 Immunomedics, Inc. Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
WO2009055653A1 (fr) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation par la technique d'accostage et verrouillage (dnl)
WO2009126558A1 (fr) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Procédé modulaire pour préparer des cytokines tétramères avec une pharmacocinétique améliorée par la technologie « dock-and-lock » (dnl)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
See also references of WO2011056721A2 *

Also Published As

Publication number Publication date
IN2012DN02692A (fr) 2015-09-04
CN102573902A (zh) 2012-07-11
WO2011056721A2 (fr) 2011-05-12
WO2011056721A3 (fr) 2011-10-13
AU2010315432A1 (en) 2012-04-12
EP2496256A2 (fr) 2012-09-12
CA2776563A1 (fr) 2011-05-12

Similar Documents

Publication Publication Date Title
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
EP2629801A4 (fr) Effets synergiques entre des conjugués d'anticorps et de médicament à base d'auristatine et des inhibiteurs de la voie pi3k-akt-mtor
EP2203470A4 (fr) Vaccins et composants vaccinaux permettant d'inhiber des cellules microbiennes
EP2326718A4 (fr) Peptides d'épitope inhbb et vaccins les contenant
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
IL200551A0 (en) Solid pharmaceutical and vaccine dose
IL209054A0 (en) Solid pharmaceutical formulations comprising bibw 2992
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
IL187511A0 (en) Lipases for pharmaceutical use
EP2303912A4 (fr) Peptides d épitope de cdca1 et vaccins contenant ceux-ci
HUE037105T2 (hu) Eljárások és készítmények tumorok megsemmisítésére
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL208370A0 (en) Improved formulations for poorly permeable active pharmaceutical ingredients
EP2393496A4 (fr) Vaccins améliorés pour le papillomavirus humain et leurs procédés d'utilisation
EP2408912A4 (fr) Peptides foxm1 et vaccins contenant ceux-ci
EP2507256A4 (fr) Oligopeptides imp-3 et vaccins les comprenant
GB0900772D0 (en) Live vaccine strains of francisella
EP2408913A4 (fr) Peptides neil3 et vaccins les comprenant
EP2321411A4 (fr) Peptides épitopes de melk et vaccins les contenant
SI2320739T1 (sl) Farmacevtski sestavki in postopki za njihovo stabiliziranje
EP2222693A4 (fr) Mutants de lysine décarboxylase, vaccins contre la périodontite et leurs procédés d'utilisation
EP2220228A4 (fr) Compositions pharmaceutiques et procédés permettant d'administrer des acides nucléiques dans des cellules
FR2932388B1 (fr) Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c
FR2912314B1 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
ZA201104614B (en) Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130619

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/56 20060101ALI20130613BHEP

Ipc: C07K 16/28 20060101ALI20130613BHEP

Ipc: A61K 47/48 20060101ALI20130613BHEP

Ipc: C07K 14/52 20060101ALI20130613BHEP

Ipc: A61P 35/00 20060101ALI20130613BHEP

Ipc: C07K 16/46 20060101AFI20130613BHEP

Ipc: C07K 16/24 20060101ALI20130613BHEP

Ipc: C07K 16/30 20060101ALI20130613BHEP

Ipc: C07K 16/44 20060101ALI20130613BHEP

Ipc: A61K 39/395 20060101ALI20130613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150401